Review
Oncology
Juan Sun, Xianze Wang, Zimu Zhang, Ziyang Zeng, Siwen Ouyang, Weiming Kang
Summary: Research on predicting the sensitivity of NACT for gastric cancer spans multiple aspects including biomarkers, inflammatory indicators, and imaging assessments. While numerous studies have been conducted on biomarkers, a unified conclusion has not yet been reached. Inflammatory indicators have been shown to be associated with the survival and prognosis of patients undergoing NACT, and imaging assessments such as CT, MRI, and PET may offer unique advantages in early screening for NACT-sensitive patients through careful integration and optimization.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Lorenzo Gervaso, Stefania Pellicori, Chiara A. Cella, Vincenzo Bagnardi, Florian Lordick, Nicola Fazio
Summary: The study highlights the importance of identifying molecular biomarkers in patients undergoing neoadjuvant chemotherapy for locally advanced resectable gastric or esophagogastric junction cancer. Despite improvements in prognosis, relapse-related death remains a major challenge, and further research is needed to understand which patients will benefit from peri-operative treatment. Biomarkers such as HER2, MSI, and EBV have shown promise but require more methodologically sound clinical trials to guide treatment choices effectively.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Qinmei Xu, Zeyu Sun, Xiuli Li, Chen Ye, Changsheng Zhou, Longjiang Zhang, Guangming Lu
Summary: The study developed and evaluated machine learning models using baseline and restaging CT for predicting and early detecting pathological downstaging in AGC patients receiving neoadjuvant chemotherapy. The radiomics models performed well on prediction and early detection tasks, potentially assisting surgical decision-making for AGC patients.
EUROPEAN RADIOLOGY
(2021)
Review
Medicine, Research & Experimental
Nicolae Bacalbasa, Camelia Diaconu, Bogdan Socea, Florentina Gherghiceanu, Cornel Savu, Mihai Dimitriu, Irina Balescu, Ioan Cordos
Summary: For advanced-stage gastric cancer, preoperative treatments such as laparoscopic heated intraperitoneal chemotherapy, perioperative heated intraperitoneal chemotherapy, and neoadjuvant systemic and peritoneal chemotherapy are key in improving survival rates and prolonging lifespan for patients.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Multidisciplinary Sciences
Song Li, Wenbin Yu, Fei Xie, Haitao Luo, Zhimin Liu, Weiwei Lv, Duanbo Shi, Dexin Yu, Peng Gao, Cheng Chen, Meng Wei, Wenhao Zhou, Jiaqian Wang, Zhikun Zhao, Xin Dai, Qian Xu, Xue Zhang, Miao Huang, Kai Huang, Jian Wang, Jisheng Li, Lei Sheng, Lian Liu
Summary: The combination of immune checkpoint inhibitors, antiangiogenesis agents, and chemotherapy showed activity in the neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer. Pathological responses correlated with microsatellite instability status, PD-L1 expression, and tumor mutational burden. Further validation in large randomized trials is warranted.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jian-Xian Lin, Yi-Hui Tang, Guan-Jie Lin, Yu-Bin Ma, Jacopo Desiderio, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Chao-Hui Zheng, Amilcare Parisi, Mark J. Truty, Chang-Ming Huang
Summary: This cohort study compares the survival rates of patients with locally advanced gastric cancer who received adjuvant chemotherapy (AC) and those who did not after neoadjuvant chemotherapy followed by surgery. The study found that AC was associated with improved survival in patients with a lymph node ratio of at least 9%. These findings suggest that the lymph node ratio could be useful in AC selection for locally advanced gastric cancer in future decision-making processes.
Article
Oncology
Xin Wang, Dong-Bing Zhao, Lin Yang, Yihebali Chi, Hong Zhao, Li-Ming Jiang, Jun Jiang, Yuan Tang, Ning Li, Wen-Yang Liu, Li-Zhou Dou, Shuang-Mei Zou, Li-Yan Xue, Jian-Song Ren, Yan-Tao Tian, Xu Che, Chun-Guang Guo, Xiao-Feng Bai, Yue-Min Sun, Shu-Lian Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Ye-Xiong Li, Jing Jin
Summary: This study compared the efficacy and safety of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced gastric cancer. The results showed that neoadjuvant chemoradiotherapy resulted in better tumor regression but did not improve the R0 resection rate. There was no significant difference in postoperative complications between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Zining Liu, Yinkui Wang, Fei Shan, Xiangji Ying, Yan Zhang, Shuangxi Li, Yongning Jia, Rulin Miao, Kan Xue, Zhemin Li, Ziyu Li, Jiafu Ji
Summary: The study found that adjusting treatment based solely on postoperative pathological evaluation may not be enough to effectively treat poor responders among locally advanced gastric cancer patients. Treatment changes require a more careful clinical track and multifaceted assessment.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Anna S. Koerner, Ryan H. Moy, Sandra W. Ryeom, Sam S. Yoon
Summary: Gastric cancer is a common and deadly disease worldwide. Many patients are diagnosed with unresectable advanced disease due to the ambiguous symptoms. However, some patients have locally advanced gastric cancer (LAGC), which can be treated with surgical resection and perioperative chemotherapy. The optimal treatment for LAGC varies for different subtypes, but promising treatments based on molecular subtypes and biomarkers of LAGC are on the horizon.
Review
Oncology
Caroline Fong, Edwina Johnston, Naureen Starling
Summary: Gastric cancer requires a multimodality approach to achieve optimal curative rates. Preferences for neoadjuvant and adjuvant approaches vary across the globe, but a multimodal approach provides clear survival benefits compared to surgery alone. However, the completion rates of adjuvant therapy are low, highlighting the need for patient selection optimization and individualized treatment strategies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Immunology
Qi Jiang, Weizhen Liu, Xiangyu Zeng, Chenggang Zhang, Yuqiang Du, Liwu Zeng, Yuping Yin, Jun Fan, Ming Yang, Kaixiong Tao, Peng Zhang
Summary: This study found that compared to neoadjuvant chemotherapy alone, neoadjuvant chemotherapy plus tislelizumab significantly improved the efficacy and R0 resection rate of locally advanced gastric cancer (LAGC) without increasing the incidence of perioperative complications.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Yasushi Sato, Koichi Okamoto, Tomoyuki Kawaguchi, Fumika Nakamura, Hiroshi Miyamoto, Tetsuji Takayama
Summary: Neoadjuvant chemotherapy (NAC) is an effective therapeutic option for locally advanced gastric cancer (LAGC), but its therapeutic effect is unpredictable due to tumor heterogeneity and a lack of predictive biomarkers. Researchers are focusing on biomarkers such as metabolic enzymes, nucleotide excision repair, and microsatellite instability, as well as noninvasive liquid biopsy detection methods such as miRNA and exosome detection, to guide the choice of preoperative treatment.
Article
Oncology
Zhihao Zhou, Yong Ren, Zhimei Zhang, Tianpei Guan, Zhixiong Wang, Wei Chen, Tedong Luo, Guanghua Li
Summary: This study evaluated a deep learning (DL)-based biomarker derived from histopathological images to predict the pathological response to neoadjuvant chemotherapy in patients with gastric cancer.
Article
Oncology
Tongbo Wang, Yingtai Chen, Lulu Zhao, Hong Zhou, Chaorui Wu, Xiaojie Zhang, Aiping Zhou, Jing Jin, Dongbing Zhao
Summary: This study suggests that neoadjuvant therapies can improve survival outcomes in patients with locally advanced gastric cancer compared to surgery followed by adjuvant chemotherapy, especially for those who receive neoadjuvant chemoradiation. Neoadjuvant therapy can also increase the pathological complete response rate, improve disease-free survival, and local-recurrence-free survival rates.
